Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918336 | 1.00 | CYP2D6 (0.63) | CYP2D6CYP1A2KMT2ACYP2C19KDM4E | |
| SCHEMBL973107 | 0.84 | CYP3A4 (0.62) | CYP2D6CYP1A2KMT2ACYP2C19KDM4E | |
| SCHEMBL12948677 | 0.84 | CYP3A4 (0.62) | CYP2D6CYP1A2KMT2ACYP2C19KDM4E | |
| SCHEMBL973106 | 0.84 | ABCG2 (0.69) | CYP2D6CYP1A2KMT2ACYP2C19KDM4E | |
| SCHEMBL11405387 | 0.84 | ABCG2 (0.69) | CYP2D6CYP1A2KMT2ACYP2C19KDM4E | |
| SCHEMBL8854345 | 0.81 | CYP2D6 (0.58) | CYP2D6CYP1A2KMT2ACYP2C19KDM4E | |
| SCHEMBL970864 | 0.81 | MAPT (0.60) | CYP2D6CYP1A2KMT2ACYP2C19KDM4E | |
| SCHEMBL979447 | 0.80 | CYP3A4 (0.58) | CYP2D6CYP1A2KMT2ACYP2C19MEN1 | |
| SCHEMBL979445 | 0.80 | CYP1B1 (0.65) | CYP2D6CYP1A2KMT2ACYP2C19KDM4E | |
| SCHEMBL12948651 | 0.80 | CYP3A4 (0.58) | CYP2D6CYP1A2KMT2ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875408-B2 | comprising photobleachable organic materials can be bleached by 193 nm light, and brought back to their original state by stimuli after exposure; to improve the aerial image effectively seen by the photoresist and thereby improve the contrast | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080182178-A1 | Bleachable materials for lithography | GLOBALFOUNDRIES U.S. INC. | 2008-07-31 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1242352-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| WO-2001046110-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | CYP2D6 1885/4885CYP1A2 795/4885KMT2A 2333/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | CYP2D6 1826/4885CYP1A2 792/4885KMT2A 2276/4885 |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | CYP2D6 1861/4885CYP1A2 655/4885KMT2A 2196/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | CYP2D6 1861/4885CYP1A2 655/4885KMT2A 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.